Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data
Contraception · 2025
DOI: 10.1016/j.contraception.2024.110786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contraception, 2025. Verfasst von Tanja Boehnke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Statistics and Methodology, ZEG Berlin - Center for Epidemiology and Health Research, Berlin, Germany. Electronic address: t.boehnke@zeg-berlin.de. Hauptthemen laut MEDLINE: Psychotropic Drugs, Contraceptives, Oral, Combined, Progestins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To assess the risk of contraceptive failure and adverse events (AEs) associated with the type of progestin when coadministered with psychotropic drugs within a routine clinical practice setting. STUDY DESIGN: A pooled analysis of four large, prospective, multinational cohort studies including women with a new prescription of combined oral contraceptives (COCs) and concomitant psychotropic drug use from 13 European countries and the United States. We determined the frequency of contraceptive failures and AEs within 6 months after COC initiation by progestin type. Furthermore, we calculated crude and propensity score weighted incidence rate ratios with corresponding 95% confidence intervals via Poisson regression. Covariates used for propensity score estimation included age, body mass index, smoking, medical history, history of hormonal contraceptive use, and education level. RESULTS: Our analysis comprised 7679 COC users reporting psychotropic drug use at baseline. The most common progestin type was drospirenone (30.0%) followed by norethisterone acetate/norethindrone acetate (20.5%), levonorgestrel (17.3%), norgestimate (11.6%), norethindrone (5.7%), nomegestrol/nomegestrol acetate (5.6%), desogestrel (4.9%), and dienogest (4.4%). Overall, 39 (0.5%) contraceptive failures and 156 (2.0%) AEs occurred within the first 6 months of follow-up. Head-to-head comparison of different progestins against levonorgestrel regarding AEs showed a significantly lower risk for drospirenone (weighted incidence rate ratio 0.5, 95% confidence interval [0.3-0.9]), while no difference was observed for other progestins. CONCLUSIONS: Among women using psychotropic drugs, drospirenone was associated with a lower risk of AEs compared to levonorgestrel, while other progestins showed no significant differences. The number of contraceptive failures was low across progestins. IMPLICATIONS: Compared to levonorgestrel, drospirenone has shown a reduced risk of adverse events when coadministered with psychotropic drugs, whereas other common progestins showed no significant differences. Contraceptive failures were rare across progestins. This analysis provides valuable real-world data on potential drug interactions and may be used for future updates of evidence-based guidelines on contraception.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Statistics and Methodology, ZEG Berlin - Center for Epidemiology and Health Research, Berlin, Germany. Electronic address: t.boehnke@zeg-berlin.de.
- Data Management, ZEG Berlin - Center for Epidemiology and Health Research, Berlin, Germany.
- Statistics and Methodology, ZEG Berlin - Center for Epidemiology and Health Research, Berlin, Germany.
- Project Management, ZEG Berlin - Center for Epidemiology and Health Research, Berlin, Germany.
- Department of Applied Health Sciences, University of Applied Sciences, Bochum, Germany.
- LVR-University Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany; Center for Translational Neuro and Behavioral Sciences, University of Duisbur…
Zitieren
APA
Boehnke, T., Franke, C., Bauerfeind, A., Heinemann, K., Kolberg-Liedtke, C., & Koelkebeck, K. (2025). Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data. Contraception. https://doi.org/10.1016/j.contraception.2024.110786
Vancouver
Boehnke T, Franke C, Bauerfeind A, Heinemann K, Kolberg-Liedtke C, Koelkebeck K. Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data. Contraception. 2025. doi:10.1016/j.contraception.2024.110786
BibTeX
@article{Boehnke2025,
author = {Boehnke, Tanja and Franke, Christian and Bauerfeind, Anja and Heinemann, Klaas and Kolberg-Liedtke, Cornelia and Koelkebeck, Katja},
title = {Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data},
journal = {Contraception},
year = {2025},
doi = {10.1016/j.contraception.2024.110786}
}
EUVIMED